Literature DB >> 29626596

Renal histology in a patient with TAFRO syndrome: a case report.

Hiroki Mizuno1, Akinari Sekine2, Masahiko Oguro2, Yoichi Oshima2, Masahiro Kawada2, Keiichi Sumida2, Masayuki Yamanouchi2, Noriko Hayami2, Tatsuya Suwabe2, Rikako Hiramatsu2, Eiko Hasegawa2, Junichi Hoshino2, Naoki Sawa2, Takashi Fujii3, Kenmei Takaichi4, Kenichi Ohashi5, Yoshifumi Ubara4.   

Abstract

An 84-year-old Japanese man was admitted due to anasarca, thrombocytopenia, systemic inflammation, and progressive renal insufficiency, resistance to diuretics, glucocorticoid therapy, and plasma exchange. Renal biopsy showed diffuse endocapillary proliferation and mesangiolysis without any immune deposits. Tocilizumab suppressed systemic inflammation, resulting in improvement of anasarca and renal dysfunction, but thrombocytopenia persisted and platelet-associated IgG antibody was elevated. Although romiplostim was effective for thrombocytopenia, the patient died of aspiration pneumonia after cerebral hemorrhage. Autopsy showed hyaline vascular-type Castleman disease-like lymphadenopathy and reticulin myelofibrosis with an increase of megakaryocytes. Renal finding showed that endocapillary injury improved, and collapsed glomeruli were noted. This patient fitted the criteria for TAFRO (thrombocytopenia [T], anasarca [A], fever [F], reticulin myelofibrosis [R], and organomegaly [O]) syndrome. The clinical course suggests that 2 factors, including overproduction of interleukin 6 and autoimmune-mediated thrombocytopenia via thrombopoietin receptor, may have contributed to the pathogenesis of TAFRO syndrome in this patient.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multicentric Castleman disease; TAFRO syndrome; Thrombocytopenia; Thrombotic microangiopathy; Tocilizumab

Mesh:

Substances:

Year:  2018        PMID: 29626596     DOI: 10.1016/j.humpath.2018.03.021

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; David Wu; Aaron Goodman; Raymond Wong; Amy Chadburn; Sunita Nasta; Gordan Srkalovic; Sudipto Mukherjee; Heather Leitch; Raj Jayanthan; Simone Ferrero; Yasuharu Sato; Steve Schey; Angela Dispenzieri; Eric Oksenhendler; Pier Luigi Zinzani; Mary Jo Lechowicz; Christian Hoffmann; Naveen Pemmaraju; Adam Bagg; Alexander Fossa; Megan S Lim; Frits van Rhee
Journal:  Am J Hematol       Date:  2020-09-25       Impact factor: 13.265

2.  The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome.

Authors:  Hiroki Mizuno; Naoki Sawa; Shun Watanabe; Daisuke Ikuma; Akinari Sekine; Masahiro Kawada; Masayuki Yamanouchi; Eiko Hasegawa; Tatsuya Suwabe; Junichi Hoshino; Kenmei Takaichi; Keiichi Kinowaki; Takeshi Fujii; Kenichi Ohashi; Michio Nagata; Yutaka Yamaguchi; Yoshifumi Ubara
Journal:  Kidney Int Rep       Date:  2020-05-19

Review 3.  Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.

Authors:  Amélie Leurs; Viviane Gnemmi; Arnaud Lionet; Loïc Renaud; Jean-Baptiste Gibier; Marie-Christine Copin; Eric Hachulla; Pierre-Yves Hatron; David Launay; David Fajgenbaum; Louis Terriou
Journal:  Front Immunol       Date:  2019-06-28       Impact factor: 8.786

4.  HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis.

Authors:  Maria Brito Nunes; Samuel Rotman; Francois-Regis Duss; Matthieu Halfon
Journal:  BMJ Case Rep       Date:  2020-01-06

5.  Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.

Authors:  Qianyun Zhou; Yuanyuan Zhang; Guangping Zhou; Jihong Zhu
Journal:  BMC Nephrol       Date:  2020-11-23       Impact factor: 2.388

Review 6.  Updates on the diagnosis and management of multicentric Castleman disease.

Authors:  Ya-Ju Wu; Kuei-Ying Su
Journal:  Tzu Chi Med J       Date:  2020-07-29

7.  TAFRO syndrome presenting as intrahepatic cholangitis on autopsy.

Authors:  Hiroaki Nishioka; Shogo Nishino; Aisa Yoshizaki; Shigeo Hara
Journal:  Clin Case Rep       Date:  2021-03-03

8.  Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?

Authors:  Yoshito Nishimura; Asami Nishikori; Haruki Sawada; Torrey Czech; Yuki Otsuka; Midori Filiz Nishimura; Hiroki Mizuno; Naoki Sawa; Shuji Momose; Kumiko Ohsawa; Fumio Otsuka; Yasuharu Sato
Journal:  J Clin Exp Hematop       Date:  2022-03-05

9.  TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.

Authors:  Yoshikuni Nagayama; Mizuki Yamano; Motoka Yagame; Tomoyuki Nariyama; Mikiko Takahashi; Masashi Kawamoto; Katsuyuki Matsui
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

10.  Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.

Authors:  Keiichiro Kadoba; Daisuke Waki; Keisuke Nishimura; Hiroki Mukoyama; Rintaro Saito; Hiroyuki Murabe; Toshihiko Yokota
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.